Physician profile
Luana Pillon
NPI 1679567309
$8,586.72
in general payments reported to CMS, 2019-2025
25 companies · $2,471 in 2025
The $2,471 reported for 2025 was more than what 91% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $557 · 2020: $62.67 · 2021: $1,976 · 2022: $405 · 2023: $791 · 2024: $2,324 · 2025: $2,471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,261 · Travel and Lodging: $869 · Education: $455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,261.15 |
| Travel and Lodging | $869.38 |
| Education | $455.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $1,958.68 | 2020-2023 | |
| Travere Therapeutics, INC. | $1,655.82 | 2023-2025 | |
| Amgen INC. | $1,351.74 | 2019-2025 | Krystexxa, Uplizna, Otezla |
| Alexion Pharmaceuticals, INC. | $453.04 | 2019-2024 | Ultomiris |
| Glaxosmithkline, LLC. | $413.06 | 2020-2025 | Benlysta, Jesduvroq |
| Novo Nordisk INC | $387.85 | 2022-2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $317.32 | 2024-2025 | Libtayo |
| Ani Pharmaceuticals, INC. | $285.00 | 2023-2025 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $207.03 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $205.44 | 2021-2025 | Saphnelo, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $193.46 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $161.91 | 2023-2025 | Lupkynis |
| E.R. Squibb & Sons, L.L.C. | $145.86 | 2024 | Sotyktu |
| Otsuka America Pharmaceutical, INC. | $145.17 | 2024 | |
| Abbott Laboratories | $140.00 | 2024 | Freestyle Libre 3 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $129.24 | 2019 | |
| Viiv Healthcare Company | $124.84 | 2023 | Dovato |
| Vifor Pharma, INC. | $114.28 | 2024-2025 | Veltassa |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $52.97 | 2022-2024 | Jynarque |
| Akebia Therapeutics INC | $49.22 | 2024 | Vafseo |
| Calliditas Therapeutics US INC. | $29.47 | 2025 | Tarpeyo |
| Genentech USA, INC. | $20.97 | 2025 | Gazyva |
| Opko Pharmaceuticals, LLC | $16.21 | 2023 | Rayaldee |
| Mallinckrodt Hospital Products INC. | $14.25 | 2022 | |
| Pharmacosmos Therapeutics INC. | $13.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luana Pillon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.